Pentoxifylline Therapy for Late-Onset Sepsis in Preterm Infants: A Randomized Controlled Trial

Pediatric Infectious Disease Journal

Volumn 34, Issue 6, 2015, Pages e143-e148

  Shabaan, Abd Elazeez ^a   Nasef, Nehad ^a   Shouman, Basma ^a   Nour, Islam ^a   Mesbah, Abeer ^b   Abdel Hady, Hesham ^a  

^a MANSOURA UNIVERSITY CHILDREN S HOSPITAL   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

late onset sepsis; neonatal; pentoxifylline; randomized controlled trial

Indexed keywords

C REACTIVE PROTEIN; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; ARTICLE; ASSISTED VENTILATION; BIRTH WEIGHT; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID CULTURE; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; LEUKOMALACIA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN MORBIDITY; NEWBORN MORTALITY; ONSET AGE; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROLENTAL FIBROPLASIA; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; INTRAVENOUS DRUG ADMINISTRATION; LATE ONSET DISORDER; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; INFANT, PREMATURE; LATE ONSET DISORDERS; LENGTH OF STAY; MALE; PENTOXIFYLLINE; PLACEBOS; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937687048     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000698     Document Type: Article

References (40)

1. Lawn JE, Wilczynska-Ketende K, Cousens SN., Estimating the causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol 2006 35 706 718
2. Zaidi AK, Huskins WC, Thaver D, Hospital-acquired neonatal infections in developing countries. Lancet 2005 365 1175 1188
3. Stoll BJ, Hansen N, Fanaroff AA, Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002 110 2 Pt 1 285 291
4. Tiskumara R, Fakharee SH, Liu CQ, Asia-Pacific Neonatal Infections Study Neonatal infections in Asia. Arch Dis Child Fetal Neonatal Ed 2009 94 F144 F148
5. Talbert AW, Mwaniki M, Mwarumba S, Invasive bacterial infections in neonates and young infants born outside hospital admitted to a rural hospital in Kenya. Pediatr Infect Dis J 2010 29 945 949
6. Bader D, Kugelman A, Boyko V, Israel Neonatal Network Risk factors and estimation tool for death among extremely premature infants: a national study. Pediatrics 2010 125 696 703
7. Baley JE., Neonatal sepsis: the potential for immunotherapy. Clin Perinatol 1988 15 755 771
8. Wynn J, Cornell TT, Wong HR, The host response to sepsis and developmental impact. Pediatrics 2010 125 1031 1041
9. de Bont ES, Martens A, van Raan J, Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 plasma levels in neonatal sepsis. Pediatr Res 1993 33 4 Pt 1 380 383
10. Ng PC, Li K, Wong RP, Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed 2003 88 F209 F213
11. Harris MC, D'Angio CT, Gallagher PR, Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing enterocolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J Pediatr 2005 147 462 468
12. Bajčetić M, Spasić S, Spasojević I., Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents. Shock 2014 42 179 184
13. Harris E, Schulzke SM, Patole SK., Pentoxifylline in preterm neonates: a systematic review. Paediatr Drugs 2010 12 301 311
14. Lauterbach R, Zembala M., Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 1996 155 404 409
15. Wang P, Wood TJ, Ba ZF, Pentoxifylline maintains vascular endothelial cell function during hyperdynamic and hypodynamic sepsis. Surgery 1996 120 367 373
16. Schönharting M, Musikić P, Müller R., The haemorheological and antithrombotic potential of pentoxifylline ('Trental'): a review. Pharmatherapeutica 1988 5 159 169
17. Krause PJ, Kristie J, Wang WP, Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice. Am J Pathol 1987 129 217 222
18. Vilcek J, Lee TH., Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991 266 7313 7316
19. Lauterbach R, Pawlik D, Kowalczyk D, Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999 27 807 814
20. Adel M, Awad HA, Abdel-Naim AB, Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther 2010 35 257 265
21. Akdag A, Dilmen U, Haque K, Role of pentoxifylline and/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis. Am J Perinatol 2014 31 905 912
22. Ali W, Ahmed P, Bhat MA, Pentoxifylline in the treatment of sepsis in premature infants. JK Pract 2006 13 204 207
23. Selim K, Hüseyin C, Ibrahim KH, Effect of pentoxifylline on tumor necrosis factor-alpha and interleukin-6 levels in neonatal sepsis. Med J Malaysia 2004 59 391 394
24. Lauterbach R, Pawlik D, Tomaszczyk B, Pentoxifylline treatment of sepsis of premature infants: preliminary clinical observations. Eur J Pediatr 1994 153 672 674
25. Haque KN, Pammi M., Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2011 CD004205
26. Haque KN., Definitions of bloodstream infection in the newborn. Pediatr Crit Care Med 2005 6 3 Suppl S45 S49
27. Ng PC., Diagnostic markers of infection in neonates. Arch Dis Child Fetal Neonatal Ed 2004 89 F229 F235
28. Marik PE, Lipman J., The definition of septic shock: implications for treatment. Crit Care Resusc 2007 9 101 103
29. Kissoon N, Orr RA, Carcillo JA., Updated American College of Critical Care Medicine-pediatric advanced life support guidelines for management of pediatric and neonatal septic shock: relevance to the emergency care clinician. Pediatr Emerg Care 2010 26 867 869
30. Bonavida B., Immunomodulatory effect of tumor necrosis factor. Biotherapy 1991 3 127 133
31. Gaffney PJ., Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta 1975 65 109 115
32. Bell MJ, Ternberg JL, Feigin RD, Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978 187 1 7
33. Woods WG, Luban NL, Hilgartner MW, Disseminated intravascular coagulation in the newborn. Am J Dis Child 1979 133 44 46
34. Frost BL, Jilling T, Caplan MS., The importance of pro-inflammatory signaling in neonatal necrotizing enterocolitis. Semin Perinatol 2008 32 100 106
35. Travadi J, Patole S, Charles A, Pentoxifylline reduces the incidence and severity of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2006 60 185 189
36. Erdener D, Bakirtas F, Alkanat M, Pentoxifylline does not prevent hypoxia/reoxygenation-induced necrotizing enterocolitis. An experimental study. Biol Neonate 2004 86 29 33
37. Dilek M, Kumral A, Okyay E, Protective effects of pentoxifylline on lipopolysaccharide-induced white matter injury in a rat model of periventricular leukomalasia. J Matern Fetal Neonatal Med 2013 26 1865 1871
38. Lauterbach R, Pawlik D, Zembala M, Pentoxyfylline in and prevention and treatment of chronic lung disease. Acta Paediatr Suppl 2004 93 20 22
39. Lauterbach R, Szymura-Oleksiak J, Pawlik D, Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med 2006 19 433 438
40. Howe LM., Novel agents in the therapy of endotoxic shock. Expert Opin Investig Drugs 2000 9 1363 1372